Bessemer Group
JNCE

Bessemer Group’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Bessemer Group’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-27,585
Closed -$187K – 2068
2022
Q1 		$187K Buy
27,585
+15,718
+132% +$112K ﹤0.01% 841
2021
Q4 		$99K Hold
11,867
– – ﹤0.01% 1005
2021
Q3 		$88K Hold
11,867
– – ﹤0.01% 962
2021
Q2 		$81K Hold
11,867
– – ﹤0.01% 986
2021
Q1 		$122K Buy
11,867
+1,700
+17% +$18.6K ﹤0.01% 856
2020
Q4 		$71K Buy
+10,167
New +$79.1K ﹤0.01% 931

Other funds holding JNCE

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return

Bessemer Group's JNCE Position: Q2 2022 in Review

Bessemer Group sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2022, closing a stake of 27,585 shares — an estimated $187K sold.

Bessemer Group first reported a position in JNCE in Q4 2020 and held it in 6 quarters. The position peaked at $187K in Q1 2022. 102 funds tracked by Wall St. Rank hold JNCE as of Q2 2022.

  • Bessemer Group reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Bessemer Group sold 27,585 Jounce Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $187K.
  • Bessemer Group first reported a position in Jounce Therapeutics, Inc. Common Stock in Q4 2020 and held it in 6 quarters.
  • Bessemer Group's Jounce Therapeutics, Inc. Common Stock position peaked at $187K in Q1 2022.
  • 102 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Bessemer Group's 13F filing for Q2 2022, filed 10 Aug 2022.